Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.42 |
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | PPARG | P37231 | 3/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1818709 | 0.94 | KMT2A (0.44) | HTTALDH1A1L3MBTL1TTRKMT2A | |
| SCHEMBL1820279 | 0.90 | ALDH1A1 (0.42) | HTTALDH1A1L3MBTL1MAPK1PARP10 | |
| SCHEMBL1821619 | 0.89 | CTNNB1 (0.49) | HTTL3MBTL1PARP10TTRKMT2A | |
| SCHEMBL1819287 | 0.88 | MAPT (0.41) | HTTALDH1A1L3MBTL1MAPK1KMT2A | |
| SCHEMBL1819393 | 0.84 | PARP1 (0.44) | HTTMAPK1KMT2ARAB9ALMNA | |
| SCHEMBL1820378 | 0.84 | KMT2A (0.40) | HTTALDH1A1L3MBTL1TTRKMT2A | |
| SCHEMBL1819152 | 0.81 | KMT2A (0.49) | ALDH1A1L3MBTL1MAPK1KMT2AMEN1 | |
| SCHEMBL1824424 | 0.79 | ALDH1A1 (0.42) | ALDH1A1L3MBTL1KMT2AMEN1LMNA | |
| SCHEMBL1820714 | 0.79 | HDAC8 (0.43) | ALDH1A1L3MBTL1KMT2AMEN1RAB9A | |
| SCHEMBL1819040 | 0.77 | MAPT (0.41) | L3MBTL1PARP10KMT2AMEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947712-B2 | Antiarthritic agents; asthma; chronic obstructive pulminary diosrders; atherosclerosis; vision defects; hepatitis; central nervous system disorders; cardiovascular disorders; wound healing agents; restenosis; cirrhosis; multiple sclerosis; glomerulonephritis; graft versus host disease; antidiabetic agent | WYETH LLC (US) | 2011-05-24 | — | — | US | disclosed |
| US-20080269213-A1 | 8-Hydroxyquinoline compounds and methods thereof | WYETH (US) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269213-A1 | 8-Hydroxyquinoline compounds and methods thereof | MMP8, MMP26, MMP9 | HTT 334/4885ALDH1A1 406/4885L3MBTL1 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.